Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 19/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.56 |
| ▸ | CCR2 | P41597 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659992 | 1.00 | KDM4E (0.58) | KDM4EMEN1APAF1ALDH1A1MAPT | |
| SCHEMBL460149 | 1.00 | KDM4E (0.58) | KDM4EMEN1APAF1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL659009 | 0.99 | KDM4E (0.56) | KDM4EMEN1APAF1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL530065 | 0.99 | KDM4E (0.56) | KDM4EMEN1APAF1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL530066 | 0.99 | KDM4E (0.56) | KDM4EMEN1APAF1ALDH1A1MAPT | |
| SCHEMBL5641548 | 0.92 | ROCK2 (0.56) | KDM4EMEN1APAF1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL659638 | 0.91 | ROCK2 (0.55) | KDM4EMEN1APAF1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL659639 | 0.91 | ROCK2 (0.55) | KDM4EMEN1APAF1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL659821 | 0.91 | ROCK2 (0.55) | KDM4EMEN1APAF1ALDH1A1MAPT | |
| SCHEMBL5823157 | 0.90 | KDM4E (0.61) | KDM4EMEN1APAF1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604218-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8604205-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| CN-103254172-A | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS INC | 2013-08-21 | — | — | CN | disclosed |
| CN-103249305-A | Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms | INSPIRE PHARMACEUTICALS INC | 2013-08-14 | — | — | CN | disclosed |
| EP-2597953-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | Inspire Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2595665-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | Inspire Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131106-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131059-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| CN-101583361-B | Cytoskeletal Active RHO Kinase Inhibitor Compounds, Compositions and Uses | INSPIRE PHARMACEUTICALS INC | 2013-01-23 | — | — | CN | disclosed |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2012-02-23 | — | — | US | disclosed |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2012-02-23 | — | — | US | disclosed |
| WO-2012015760-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012012282-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-8071779-B2 | reduces intraocular pressure; primary open-angle glaucoma; effective to influence the actomyosin interactions by leading to cellular relaxation and alterations in cell-substratum adhesions | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071779-B2 | reduces intraocular pressure; primary open-angle glaucoma; effective to influence the actomyosin interactions by leading to cellular relaxation and alterations in cell-substratum adhesions | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| CN-101583361-A | Cytoskeletal Active RHO Kinase Inhibitor Compounds, Compositions and Uses | INSPIRE PHARMACEUTICALS INC (US) | 2009-11-18 | — | — | CN | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
| WO-2008077057-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131059-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | ROCK1, ROCK2, CIT | KDM4E 1878/4885MEN1 1440/4885APAF1 1366/4885 |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | KDM4E 1941/4885MEN1 2852/4885APAF1 2291/4885 |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | KDM4E 1941/4885MEN1 2852/4885APAF1 2291/4885 |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | KDM4E 1941/4885MEN1 2852/4885APAF1 2291/4885 |
| US-20130131106-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK2, ROCK1, RHOA | KDM4E 2600/4885MEN1 1600/4885APAF1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.